Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder leading to dementia. Extracellular β-amyloid (Aβ) plaques, intracellular neurofibrillary tangles, and massive neuronal cell and synapse loss represent the main pathological hallmarks in AD brains (Storey and Cappai, 1999; Selkoe, 2002) . Apart from these classic hallmarks, increasing evidence has demonstrated uncontrolled glial activation and neuroinflammation in AD brain may contribute independently to neural dysfunction and cell death (Akiyama et al., 2000; Wyss-Coray and Mucke, 2002) . Robust activation of microglia has been found in and around the area of amyloid plaques in the AD brain, and reactive astrocytes have been shown to form a halo surrounding the amyloid plaques (Itagaki et al., 1989; Ho et al., 2005) . Additionally, numerous proinflammatory factors have been reported to be elevated in both patients with AD and transgenic animal models of AD (Griffin et al., 1989; Akiyama et al., 2000; Ruan et al., 2009) . Whether alleviation of neuroinflammation will offer therapeutic benefit for AD remains unclear. Epidemiological studies show a possible association between suppression of inflammation and reduced risk for AD (in t ' Veld et al., 2001; Vlad et al., 2008) . Therefore, drugs targeting neuroinflammation might provide benefits for the prevention and treatment of this devastating disease.
In the central nervous system, microglia and astrocytes are the major type of glial cells, and activation of these cells has been involved in all neurodegenerative diseases (Wyss-Coray and Mucke, 2002) . Nevertheless, the diverse physiological functions of glial activation might complicate the interpretation of experimental investigations and clinical observations related to AD pathology. For example, glial phagocytosis of Aβ is considered to be one key mechanism of the initial defense of the brain against the toxic accumulation of Aβ (Wyss-Coray et al., 2003; Zhang et al., 2014) . As the disease progresses, continuous glial activation by Aβ releases excessive multiple cytokines and chemokines such as tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β), monocyte chemotactic protein-1, and nitric oxide, which leads to a vicious cycle of further glial activation and neurotoxic damage through generating chronic self-sustaining inflammatory reactions (Paradisi et al., 2004; Perry et al., 2010) . This process may stimulate and even accelerate the progression of AD.
The nuclear factor kappa B (NF-κB) is a transcription factor that is involved in regulating immune and inflammatory responses (Li and Verma, 2002; Kucharczak et al., 2003) . The mammalian NF-κB family consists of RelA/p65, RelB, c-Rel, p50/ p105 (NF-κB1), and p52/p100 (NF-κB2) (Zheng et al., 2011) . These proteins can form homo-or heterodimers, which often are held captive in cytoplasm, remaining inactive. The activated NF-κB translocates to the nucleus, which leads to expression of a number of inflammatory genes, including cyclooxygenase (COX), IL-1β, and TNFα . NF-κB signaling has been proven to be involved in AD. Enhanced immunoreactivity was observed in neurons surrounding amyloid plaques in the brains of AD patients (Kaltschmidt et al., 1997) . In addition, activated NF-κB has been found in microglia of patents with AD (Mattson and Camandola, 2001) . In in vitro studies, NF-κB can be activated by Aβ in both neuronal and microglial cells (Huang et al., 2012) . Together, it suggested that activation of NF-κB plays an important role in mediating neuroinflammation in AD.
Quetiapine (Seroquel) is a novel atypical antipsychotic drug that was approved for the treatment of patients with schizophrenia (Purdon et al., 2001; Velligan et al., 2002) . Clinically, quetiapine is also used to treat psychosis in AD as well as cognition in Parkinson's disease (Juncos et al., 2004; Madhusoodanan et al., 2007) . In animal studies, quetiapine decreases the accumulation of activated astrocytes and microglia in demyelinated sites followed by cuprizone administration , modulates immune responses in an experimental autoimmune encephalomyelitis model of multiple sclerosis (Mei et al., 2012) , and inhibits NF-κB p65/p50 expression in ischemic mice (Bi et al., 2009) . In vitro studies have shown that quetiapine inhibits nitric oxide generation and TNFα release from activated microglia (Bian et al., 2008) . Although quetiapine has some beneficial effects on cognition in AD mice (Zhu et al., 2013) , there are no data published with respect to its effect on glial activation and neuroinflammation in AD mice. In the present study, we wanted to address the issue of whether glial activation and proinflammatory cytokine increases could be modulated by quetiapine through regulating the NF-κB pathway in an amyloid precursor protein (APP) and presenilin 1 (PS1) humanized knockin mouse model of AD.
Materials and Methods

Animals and Treatments
APP/PS1 double transgenic and nontransgenic mice were generated from mating between single transgenic mice expressing human mutant APP K670N/M671L (Hsiao et al., 1996) and mutant PS1 M146L (Duff et al., 1996) and chosen by the genotyping results of polymerase chain reaction. The age-and sex-matched wildtype mice were used as the controls. All mice had free access to food and water under controlled laboratory conditions. All procedures with animals were performed in accordance with the guidelines established by the Canadian Council on Animal Care and were approved by the Animal Care Committee of the University of Manitoba.
Quetiapine was obtained from AstraZeneca Pharmaceuticals (Macclesfield, UK). The drug was dissolved in sterile water and delivered to mice at the dose 5 mg/kg/d for 8 months, starting from the age of 4 months. The doses chosen referred to our previous report . APP/PS1 double transgenic mice and wild-type littermates were randomly assigned to 4 groups: nontransgenic + water (control age-and sex-matched wild-type mice), nontransgenic + quetiapine 5 mg/(kg d), transgenic + water, and transgenic + quetiapine 5 mg/(kg d).
Open Field Test
The open field test was performed in a bare square box (36 × 36 inches) made of compressed wood and painted in grey. The open field box was divided into outer and inner zones. Mice were placed in a particular corner of the arena and tracked using ANY-Maze Video Tracking Software (Stoelting, Wood Dale, IL) with a digital camera. Mice were allowed to explore the maze for 5 minutes, after which they were returned to their home cage. The maze was cleaned with 75% ethanol wipes before commencing testing with the next mouse. The time in the center and total ambulation (in meters) were taken as measures of anxiety.
Object Recognition Test
Nonspatial memory of mice was measured using the object recognition test as previously described (Clark et al., 2000) . Mice were placed into a 40 cm (width) × 40 cm (width) × 23 cm (height) Plexiglas square box. It consisted of 3 sessions: habituation, training, and retention (He et al., 2006) . During the training session, mice were individually placed in the activity box for 10 minutes of free exploration, in which 2 identical objects (objects A1 and A2) were positioned in 2 adjacent corners. During the retention session for the short-term memory test, mice were placed back into the same box 1 hour later containing 1 of the previous objects (A1 or A2) and a novel object (B) for a 5-minute testing session. During the retention session for the long-term memory test, animals were subsequently placed back into the same box 23 hours after the short-term memory test (24 hours after the training session) for 5 minutes of free exploration, where object B was replaced by a novel object C. During the retention session, the time spent exploring the novel object (B or C) was used to measure memory function. Object exploration was considered as a mouse's nose touching the object or was facing and within 2 cm to the object (Oh et al., 2010) . Exploratory activity of each object was recorded for both training and testing sessions using ANY-Maze Video Tracking Software (Stoelting) and analyzed offline with the experimenter blinded to treatment and genotypes.
Tissue Processing
After the above behavioral tests, animals were anesthetized and perfused with phosphate-buffered saline (PBS; pH 7.4). The hemispheres were separated by cutting at the midline. The cortex and hippocampus from the right hemisphere were separated and used for biochemistry analyses. The left hemisphere was post-fixed in 4% paraformaldehyde in PBS and then cryoprotected in 30% sucrose in PBS (Qing et al., 2008; He et al., 2009 ). Finally, the left hemisphere was cut into 30-μm thick coronal sections.
Immunohistochemistry
Six free-floating sections from each animal were first incubated with 0.3% H 2 O 2 in 0.01 M PBS for 30 minutes at room temperature to quench endogenous peroxidase activity, then blocked with 5% goat serum and 0.3% Triton X-100 in PBS for 1 hour, and then incubated overnight at 4°C with anti-glial fibrillary acidic protein (GFAP) mouse mAb (1:1000; Sigma, St. Louis, MO) and anti-ionized calcium binding adapter molecule 1 (Iba1) rabbit pAb (1:500; Wako Chemicals, Richmond, VA). After rinsing, the sections were incubated with appropriate biotinylated secondary antibody (1:500; Vector Laboratories, Burlingame, CA) at room temperature for 1 hour. Staining was achieved with the avidin biotin complex kit (Vector Laboratories, Burlingame, CA) and visualized with 3,3-diaminobenzidine chromogen (ThermoFisher Scientific, Waltham, MA). Slides were viewed with an Axio-Imager M2 and Zen software for image acquisition (Carl Zeiss, Jena, Germany). The immunohistochemical controls were performed as above, but with the omission of the primary antibodies. No positive immunostaining was found in any of the controls.
Western Blotting
Protein samples were resolved on 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis mini-gels under reducing conditions. They were then electrophoretically transferred onto nitrocellulose membranes. Membranes were blocked with 5% (wt/vol) nonfat dried milk in Tris-buffered saline with Tween 20 buffer and were probed at 4°C overnight with the following antibodies: a rabbit polyclonal anti-C-terminal APP (1:3000) antibody (Sigma, St. Louis, MO), a rabbit polyclonal anti-PS1 (1:1000) antibody (Cell Signaling Technology, Danvers, MA), a mouse monoclonal anti-GFAP (1:1000) antibody (Sigma), a mouse monoclonal anti-NF-κB p65 (1:500) antibody (Santa Cruz Biotechnology, CA), a mouse monoclonal anti-β-actin (1:5000) antibody (Santa Cruz), and a mouse monoclonal anti-glyceraldehyde 3 phosphate dehydrogenase (GAPDH) (1:1000) antibody (Abcam, Cambridge, MA). Blots were then incubated at room temperature for 2 hours with corresponding peroxidise-conjugated secondary antibodies. Proteins were detected by enhanced chemiluminescence (Amersham Biosciences, NJ). Band densities were quantified using the Bio-Rad Laboratories Quantity One Software (Hercules, CA). All target proteins were normalized to β-actin or GAPDH and then standardized to the corresponding control group.
Mouse Primary Microglia Culture and Treatment
Microglial cultures were prepared from mixed glial cultures as previously described (Kauppinen et al., 2008) . Briefly, cortices were dissected from 1-day-old mice in Hanks' Balanced Salt Solution (Invitrogen). Cells were dissociated by mincing, followed by incubation in trypsin for 25 minutes at 37°C with agitation. After centrifugation for 5 minutes at 1000 rpm, the cells were resuspended with Dulbecco's Modified Eagle Medium (Invitrogen) with 10% fetal bovine serum. Cells were plated on 75-cm 2 flasks at a density of 1.5 × 10 7 cells per flask and maintained in a 37°C, 5% CO 2 incubator. The medium was changed every 3 to 4 days. After 2 weeks in vitro, microglia were harvested by shaking the flasks at 200 rpm on a rotary shaker for 4 hours at 37°C. Cells were collected, washed, and seeded at a density of 1 × 10 6 cells/mL. The purity of the microglial cultures was tested by immunocytochemical staining for Iba1, a microglia marker, and for GFAP, an astrocyte marker. The purity of microglial cultures was found to be ∼95%. Also, the cellular morphology was carefully investigated under phase contrast microscope.
Synthetic Aβ 1-42 peptide (American Peptide Company, Sunnyvale, CA) was dissolved in distilled water and incubated for 1 week at 37°C before use to induce fibril formation. Primary microglia were pretreated with quetiapine (0, 10 µM) for 1 hour and then they were exposed to 0 or 25 µM Aβ in the presence of the same concentrations of quetiapine for 6 hours.
ELISA
The levels of total Aβ 40 and Aβ 42 were measured using the Human Aβ ELISA Kits following the manufacturer's protocol (InvitrogenBiosource, Camarillo, CA). Each sample was assayed in duplicate at appropriate dilutions, so that relative luminescent units fell within the range of standard curves.
The proinflammatory cytokines IL-1β and TNFα in both brain and the supernatant of cultured microglia were measured using commercial ELISA kits (Invitrogen). Assays were performed according to the manufacturer's instructions. The levels of IL-1β and TNFα in brain were corrected for total protein of tissue and dilution factor, and the final value in each group was standardized to the control group. The levels of IL-1β and TNFα in cultured microglia were expressed in picograms per milliliter.
Immunocytochemistry
Primary microglia were plated on culture slides (BD Science, Franklin Lakes, NJ). After treatment, cultured microglia were washed twice with PBS and fixed with 4% paraformaldehyde for 30 minutes. After washing twice with PBS, the cells were permeabilized with 0.2% Triton X-100 for 10 minutes and then incubated overnight with anti-NF-κB p65 (1:100) antibody (Santa Cruz) at 4°C. After washing, the cells were incubated with Alexa Fluor 594-conjugated secondary antibody (1:200, Invitrogen). Then, the cells were incubated with Alexa Fluor 488-conjugated phalloidin (Invitrogen) at room temperature for 50 minutes. Finally, the cells were stained with Hoechst 33342 (Calbiochem, Billerica, MA) for 5 minutes at room temperature. Images were taken with a fluorescence microscope (Olympus).
Statistical Analysis
All results are expressed as means ± SEM. Analyses were performed using a 2-way analysis of variance (ANOVA) followed by Newman-Keuls posthoc test for multiple comparisons. A 2-tailed t test for independent samples was used for 2-group comparisons. Differences were considered significant at P < .05.
Results
Quetiapine Improves Behavioral Performance of APP/PS1 Mice
The open field test was used to measure locomotion, exploration, and anxiety-like behavior. Two-way ANOVA analysis conducted on the data for total time spent in the central area of the field showed that genotype [F(1, 28) = 6.13, P < .05], and quetiapine [F(1, 28) = 5.80, P < .05] produced a significant change on the time spent in the center ( Figure 1a ) and there was an interaction between genotype and quetiapine [F(1, 28) = 4.10, P = .0526]. A posthoc analysis indicated that the time spent in the center in transgenic mice was less than that in control mice, which demonstrated an anxiety-like phenotype that developed in AD mice at 12 months of age. Quetiapine treatment significantly improved the decreased interaction with the center zone in transgenic mice (Figure 1a ). To evaluate whether quetiapine or genotype significantly influenced results, general locomotor activity was examined by looking at total distance travelled in the open field test. There was no difference in the total distance travelled among all the groups (Figure 1b ).
The object recognition task measures nonspatial visualdiscrimination memory in rodents and takes advantage of the mouse's unprompted nature to prefer exploring novel objects in its surroundings (Kamei et al., 2006) . In the training session, mice spent equal amounts of time on each of the 2 identical objects (Figure 1c) , indicating that the 2 objects were equally preferred. In addition, the total amount of time spent exploring the objects (A1 + A2) was similar in all mice, suggesting that genotype and quetiapine had no effect on the levels of attention and motivation of these mice for the objects. During the 1-hour retention session, all mice spent more time exploring the novel object B (Figure 1d ), indicating that transgenic mice exhibited no defects in memory for novel objects measured 1 hour after training. During the 24-hour retention test, nontransgenic mice treated with water or quetiapine were still able to discriminate between the familiar object and a novel object C ( Figure 1E ), exploring the latter for a significantly longer time. As expected, transgenic mice had no memory for the novel object C (Figure 1E) , showing an impaired long-term memory. In contrast, transgenic mice treated with quetiapine spent more time exploring the novel object C (Figure 1E ), implying quetiapine treatment significantly improved this longterm memory impairment in transgenic mice.
Quetiapine Marginally Affects Total Aβ 40 and Aβ 42 Levels in APP/PS1 Mice
To understand why quetiapine improved the behavior of APP/ PS1 mice, we next assessed the effects of quetiapine in aged APP/PS1 mice on total Aβ levels. Quantitative Aβ ELISA revealed a significant reduction of total Aβ 40 , but not Aβ 42 , in the cerebral cortex of quetiapine-treated APP/PS1 mice (P < .01) (Figure 2A-B) . In the hippocampus of APP/PS1 mice, quetiapine also showed a tendency to decrease total Aβ 40 and not Aβ 42 , but it was not statistically significant (P = .0504) (Figure 2C-D) . Given the important role of APP and PS1 on Aβ production during APP processing, e, The exploration time of mice on a familiar object (A1) and a novel object (C) in a retention trial 24 hours after training. A t test showed that transgenic mice exhibited an impaired ability to discriminate between the familiar object and a novel object C, whereas transgenic mice treated with quetiapine spent more time exploring the novel object C. Data are expressed as means ± SEM, n = 7 to 10 mice per group. *P < .05 vs Con; #P < .05 vs transgenic + water.
the expression of full-length APP and PS1 was determined by Western blot. As shown in Figure 2e , quetiapine had no influence on APP expression or processing, because the steady-state levels of full-length APP or PS1 were not altered by the treatment. These results suggest that quetiapine treatment may be capable of reducing certain Aβ species. However, this marginal effect of quetiapine on Aβ production cannot fully explain its beneficial effects in APP/PS1 mice on behavioral performance.
Quetiapine Attenuates Microglial Activation and Reduces Proinflammatory Cytokine Levels in APP/ PS1 Mice
Neuroinflammation is reflected in AD and its transgenic models brain as elevated inflammatory cytokines and chemokines and the accumulation of activated microglia, particularly occurring around amyloid plaques (Matsuoka et al., 2001) . We thus examined whether the activation of microglia was ameliorated by quetiapine treatment. The density of microglia was accessed by using the immunostaining of Iba1 antibody. Two-way ANOVA analysis showed that genotype [F(1, 25) = 26.79, P < .0001] and quetiapine [F(1, 25) = 3.96, P = .0577] produced significant changes on microglial cell density and that there was an interaction between genotype and quetiapine [F(1, 25) = 7.61, P = .0107]. A posthoc analysis indicated that the Iba1-positive cells per mm 2 were significantly increased in brains of APP/PS1 mice compared with those in brains of nontransgenic mice. Quetiapine treatment decreased microglia density in transgenic mouse brains (Figure 3a) .
To further confirm inhibitory inflammation of quetiapine in vivo, levels of proinflammatory cytokines IL-1β and TNFα in both cortex and hippocampus were determined. As shown in Figure 3b , 2-way ANOVA analysis conducted on the data for the level of IL-1β in cerebral cortex showed that genotype [F(1, 18) = 21.56, P = .0002] and quetiapine [F(1, 18) = 11.33, P = .0034] produced significant changes on the IL-1β level and that there was an interaction between genotype and quetiapine [F(1, 18) = 3.03, P = .099]. A posthoc analysis indicated that IL-1β was significantly increased in the cerebral cortex of APP/PS1 mice compared with that in the cortex of nontransgenic mice. Quetiapine treatment greatly attenuated the increase of IL-1β in the cortex of transgenic mice (Figure 3b) . Similar results were seen in the hippocampus. But the difference between transgenic mice and transgenic mice treated with quetiapine did not reach statistical significance (P = .062) ( Figure 3B ). However, there was no significant difference in the level of TNFα in both cerebral cortex and hippocampus among all the groups.
Quetiapine Inhibits Activation of Astrocytes in APP/PS1 Mice
In brains of AD patients (Mancardi et al., 1983) and transgenic AD mice models (Wirths et al., 2010) , activated astrocytes that are mainly cells that respond to the neuroinflammation process are often observed in and around the area of amyloid plaques (Itagaki et al., 1989; Matsuoka et al., 2001 ). Initially, we evaluated the reactivity of astrocytes in the transgenic mouse model of AD. There was a notable increase in activated astrocyte positive cells in the frontal cortex and hippocampus of APP/PS1 transgenic mice ( Figure 4A , c) compared with age-matched nontransgenic counterparts ( Figure 4A, a) . In contrast, the GFAP immunoreactivity was remarkably decreased in the quetiapine-treated APP/ PS1 transgenic mice ( Figure 4A, d ) compared with the nontreated counterparts ( Figure 4A, c) . This reduction was apparent both in the frontal cortex and hippocampus, indicating that astrogliosis was reduced after quetiapine treatment. More interestingly, whereas GFAP-positive cells in the frontal cortices of transgenic mice ( Figure 4A, g ) was largely diffuse, cortical GFAP staining of quetiapine-treated transgenic mice ( Figure 4A , h) appeared to be focal, which may suggest that activated astrocytes within quetiapine-treated brains are confined to smaller areas than in the brains of nontreated transgenic animals. Quantification of cell number in the cerebral cortex showed the GFAP-positive cells were significantly greater in transgenic mice compared with transgenic mice treated with quetiapine ( Figure 4B ). To confirm the immunohistochemistry results, Western blot was conducted to quantify the expression level of GFAP in cortical tissues. Two-way ANOVA analysis showed that genotype [F(1, 14) = 80.41, P < .0001] and quetiapine [F(1, 14) = 5.80, P = .0304] produced significant changes on the GFAP expression level and that there was an interaction between genotype and quetiapine [F(1, 14) = 14.87, P = .0018]. A posthoc analysis indicated that the protein level of GFAP was significantly increased in the cortex of transgenic mice compared with that in the cortex of nontransgenic mice. Quetiapine treatment prevented the up-regulation of GFAP protein content in transgenic mouse brains ( Figure 4C ). Taken together, these observations confirm the finding that quetiapine treatment suppresses the prolonged astrocyte activation associated with AD progression.
Quetiapine Reduces Proinflammatory Cytokine Levels in Aβ 1-42 -Treated Primary Microglia
To investigate the effect of quetiapine on the inflammatory response induced by Aβ 1-42 in vitro, primary microglia were pretreated with quetiapine (10 µM) for 1 hour and then with Aβ 1-42 (25 µM) for 6 hours. The amount of proinflammatory cytokine IL-1β and TNFα secreted into the culture medium from primary microglial cells was examined by ELISA. As shown in Figure 5a , 2-way ANOVA followed by Newman-Keuls posthoc test analysis revealed that exposure of microglia to Aβ increased the secreted IL-1β levels by about 5-fold, whereas quetiapine significantly attenuated Aβ-induced IL-1β secretion. A similar trend was seen in the results of TNFα (Figure 5b ). The level of TNFα was significantly increased after Aβ treatment. Although this upregulation tended to be decreased in the presence of quetiapine, this difference did not reach statistical significance.
Quetiapine Suppresses the Activation of NF-κB p65 Pathway in vivo and in vitro
To elucidate the possible mechanism of quetiapine in suppression of inflammation, the NF-κB p65 signaling pathway, which has been implicated in microglial activation and neuroinflammation, was studied. The expression of p65 in both cortex and hippocampus was determined by Western-blot analysis. As shown in Figure 6a , 2-way ANOVA analysis showed that genotype [F(1, 18) = 17.86, P < .001] and quetiapine [F(1, 18) = 5.79, P < .05] produced significant changes on the p65 expression level in cerebral cortex and that there was an interaction between genotype and quetiapine [F(1, 18) = 9.76, P < .01]. A posthoc analysis indicated that the protein level of p65 was significantly increased in the cortex of APP/PS1 transgenic mice compared with that in the cortex of nontransgenic mice. Quetiapine treatment significantly attenuated this increase in transgenic mice (Figure 6a) . Similar results were also observed in the hippocampus. These results indicated that quetiapine treatment could inhibit the activation of NF-κB p65 in APP/PS1 transgenic mice.
It has been reported that Aβ could stimulate NF-κB activation by inducing nuclear translocation (Huang et al., 2012) . The immunostaining of p65 in primary microglial cells showed that p65 was mainly located in the cytoplasm of untreated cells and Aβ 1-42 treatment induced a translocation of p65 from the cytoplasm to the nucleus, whereas quetiapine significantly attenuated the p65 translocation induced by Aβ 1-42 (Figure 6b ). These findings suggest that quetiapine might regulate the inhibition of neuroinflammation via suppressing NF-κB p65 pathway.
Discussion
A chronic administration of quetiapine in APP/PS1 transgenic mice resulted in a marked change in microglial and astrocyte activation and proinflammatory cytokine levels and an improvement in behavioral performance. These beneficial effects of quetiapine occurred when there were only marginal changes in levels of total Aβ, suggesting that the antiinflammatory effect of quetiapine may account for the majority of cognitive improvement in APP/PS1 transgenic mice. Moreover, we confirmed that quetiapine significantly reduced Aβ 1-42 -induced secretion of proinflammatory cytokines in primary cultured microglia. Furthermore, both in vitro and in vivo experiments demonstrated that quetiapine ameliorated proinflammatory cytokine increases via suppression of the activation of NF-κB pathway.
The primary clinical presentation of AD is progressive cognitive decline. As AD progresses, a number of neuropsychiatric symptoms, including depression and anxiety, are exhibited (Garcia-Alberca et al., 2008) . Twelve-month-old APP/PS1 transgenic mice showed higher anxiety levels than nontransgenic controls, as seen in decreased time spent in the center of the open field box. Quetiapine reduced heightened anxiety in transgenic mice with no significant effects on general locomotor activity. This suggests that quetiapine may have some level of anxiolytic effect. APP/PS1 mice showed nonspatial visual-discrimination memory deficits indicated by a lower exploration time of the novel object after 24-hour training in the object recognition test. This long-term retention memory deficit was significantly improved in APP/PS1 mice treated with quetiapine for 8 months, suggesting that this treatment paradigm was effective in improving the nonspatial memory.
The behavioral improvement following quetiapine treatment may be associated with its effects on Aβ pathology according to the amyloid hypothesis (Hardy and Selkoe, 2002) . However, the effect of quetiapine on levels of total Aβ was unexpectedly marginal. Only certain species in certain brain regions, such as total Aβ 40 in cerebral cortex, were significantly reduced following the treatment of quetiapine. This is inconsistent with our previous report with respect to the effect of quetiapine on Aβ pathology. He and colleagues ) have reported that quetiapine treatment significantly decreased total Aβ 40 and Aβ 42 production. Various factors, such as age, therapeutic time window, and duration of treatment, could be involved in showing this difference. For example, in this present study, total Aβs were measured in relatively old (12 month old) APP/PS1 transgenic mice, whereas they were evaluated in much younger mice in our previous report. Additionally, we started quetiapine administration after the onset of overt amyloid pathology beginning at the age of 4 months as opposed to 2 months old in the previous study. Given that amyloid plaques account for the majority of total Aβs, growing evidence has shown that the severity of amyloid plaques in the brain does not correlate well with the degree of cognitive impairment in AD patients (Schmitz et al., 2004) . Therefore, we reasoned that the capacity of quetiapine to improve behavioral performance may be related to the antiinflammatory effects of quetiapine.
Numerous studies show the presence of a number of markers of inflammation in the AD brain: accumulation of activated microglia occurring mainly around amyloid plaques accompanied by excessive or dysregulated release of proinflammatory cytokines and chemokines, which contributes to neuronal death and degeneration (Lucin and Wyss-Coray, 2009 ). It has been well known that higher inflammatory levels are related to higher risk of cognitive impairment (Rosano et al., 2012) . In the present study, the activation of microglia observed in the hippocampus of APP/PS1 transgenic mice, as well as a strong increase of IL-1β but not TNFα compared with the nontransgenic mice, was greatly reduced following quetiapine treatment, suggesting that quetiapine could have antiinflammatory effects. To confirm, quetiapine's antiinflammatory effects were tested on primary microglia culture, which was activated by Aβ. In agreement with our animal findings, quetiapine drastically decreased the release of both IL-1β and TNFα in microglial culture treated with Aβ 1-42 . Furthermore, our study has also shown that the doses of Aβ 1-42 (25 µM) used in this study did not affect microglial cell viability (data not shown). As these proinflammatory mediators in turn further activate microglia creating a self-perpetuating vicious cycle by which inflammation induces further neuronal damage (Paradisi et al., 2004; Perry et al., 2010) , blocking these cytokines by quetiapine possibly alleviates the chronic propagating inflammation associated with AD, which could help protect neurons and eventually attenuate behavioral impairment. Thus, quetiapine could ameliorate behavioral deficits through inhibiting brain inflammation in an APP/PS1mouse model of AD.
Apart from microglia, astrocytes are also recruited during the inflammation process. Astrogliosis process has already been considered as another feature of AD, and there are many studies showing that it is an important source of oxidative stress in AD patients (Wyss-Coray and Mucke, 2002; Paradisi et al., 2004) . Quetiapine, on the other hand, has been well studied for decreasing the increase of reactive astrocytes in different animal models of global ischemia (Yan et al., 2007) , cuprizon-induced schizophrenia , and multiple sclerosis (Mei et al., 2012) . To date, there has been no report on the effects of quetiapine on astrogliosis in APP/PS1 mice. In the present study, astrocyte numbers and GFAP expression in the cerebral cortex of APP/PS1 mice were significantly reduced by chronic administration of quetiapine. This effect seemed to be mainly due to the decrease of diffusely distributed astrocytes, since both transgenic and transgenic mice with quetiapine showed comparable numbers of astrocyte clusters.
NF-κB is known to be a critical regulator of inflammation by acting as an essential transcription factor for induction of COX2, inducible nitric oxide synthase (iNOS), IL-1β, and TNFα . It has been shown that Aβ can directly stimulate microglia through the NF-κB signaling pathway, resulting in increased secretion of cytokines, chemokines, and adhesion molecules (Wyss-Coray and Rogers, 2012) . In turn, some proinflammatory cytokines activate NF-κB and lead to a detrimental cycle of neuroinflammation and neurodegeneration. Moreover, studies have shown that NF-κB is activated in both glial cells and neurons in the brains of AD patients as well as in cultured neurons and glia following Aβ stimulation (Kaltschmidt et al., 1997; Mattson and Camandola, 2001; Huang et al., 2012) . Suppression of NF-κB ameliorates astrogliosis in APP/PS1 transgenic mice ). More importantly, our previous study has shown that quetiapine decreased p50/p65 expression levels in mice subject to global cerebral ischemia (Bi et al., 2009) . Therefore, to further understand the molecular mechanism of the effects of quetiapine on the expression of IL-1β and TNFα and subsequent glial activation, the expression of NF-κB subunit p65 was analyzed in brains using Western blots. Consistent with previous reports, the present study showed increased expression of NF-κB p65 subunit in both cortex and hippocampus of APP/PS1 transgenic mice. Quetiapine effectively ameliorated the activation of NF-κB in these mice, suggesting the effects of quetiapine against the increased levels of proinflammatory cytokines may be in part attributed to its ability of inhibition of NF-κB p65 expression. Moreover, the activation of NF-κB requires it to translocate from the cytosol to the nucleus and binds to its cognate DNA-binding sites, leading to expression of inflammatory mediators (Kucharczak et al., 2003) . Our in vitro study has demonstrated that p65 are translocated into nucleus following Aβ 1-42 stimulation, while quetiapine treatment can reverse this translocation.
Many inflammatory mediators such as IL-1β, TNFα, COX, and iNOS are believed to play a vital role in the inflammatory process of AD, because they have been reported to be elevated in the plasma, brains, and cerebrospinal fluid of patients with AD as well as transgenic animal models of AD (Griffin et al., 1989; Blum-Degen et al., 1995; Akiyama et al., 2000; Galimberti et al., 2006; Ruan et al., 2009 ). IL-1β and TNFα represent downstream targets that are regulated by the transcription factor NF-κB in the inflammatory cascade, which is an attractive candidate as a therapeutic target. Furthermore, NF-κB has also been directly implicated in APP processing. The activity of the β-secretase-1 (BACE1) promoter is controlled by a NF-κB-dependent pathway in the presence of excessive Aβ (Buggia-Prevot et al., 2008) , whereas inhibition of NF-κB signaling pathway can enhance α-secretase activity, which is responsible for the benign, nonamyloidogenic processing of APP (Lee et al., 2009) . Therefore, suppressing the NF-κB signaling pathway should not only effectively inhibit individual proinflammatory mediators such as IL-1β and TNFα in AD but also reduce Aβ production. Despite our finding that quetiapine showed only a minimal effect on total Aβ production in 12-month-old transgenic mice, levels of the soluble forms of Aβ 40 and Aβ 42 were significantly reduced following quetiapine treatment in another study (Zhu et al., 2013) . The exact mechanism by which quetiapine specifically reduces only soluble Aβs is yet unknown, but its result is significant, since soluble Aβ specifically is believed to be the primary driver of AD-related pathogenesis, resulting in glial activation, synapse loss, and neuronal cell death (Hardy and Selkoe, 2002; Tanzi and Bertram, 2005) . We believe that quetiapine may be an efficacious and promising treatment for AD because of its multiple effects, from suppressing the NF-κB pathway to reducing inflammation and soluble Aβs.
Overall, the findings reported here confirmed glial activation and proinflammatory cytokine overproduction as a common pathophysiologic mechanism and potential therapeutic target in AD. This study is the first description revealing that quetiapine improves behavioral performance while attenuating microglial and astrocyte activation in APP/PS1 transgenic mice and reduces proinflammatory cytokine levels in vivo and in vitro, which may be related to its inhibition of NF-κB activation.
